1837 related articles for article (PubMed ID: 33607284)
21. In silico mutagenesis of human ACE2 with S protein and translational efficiency explain SARS-CoV-2 infectivity in different species.
Delgado Blanco J; Hernandez-Alias X; Cianferoni D; Serrano L
PLoS Comput Biol; 2020 Dec; 16(12):e1008450. PubMed ID: 33284795
[TBL] [Abstract][Full Text] [Related]
22. Molecular docking simulation reveals ACE2 polymorphisms that may increase the affinity of ACE2 with the SARS-CoV-2 Spike protein.
Calcagnile M; Forgez P; Iannelli A; Bucci C; Alifano M; Alifano P
Biochimie; 2021 Jan; 180():143-148. PubMed ID: 33181224
[TBL] [Abstract][Full Text] [Related]
23. Critical ACE2 Determinants of SARS-CoV-2 and Group 2B Coronavirus Infection and Replication.
Adams LE; Dinnon KH; Hou YJ; Sheahan TP; Heise MT; Baric RS
mBio; 2021 Mar; 12(2):. PubMed ID: 33727353
[TBL] [Abstract][Full Text] [Related]
24. Angiotensin-Converting Enzyme 2 (ACE2) in the Pathogenesis of ARDS in COVID-19.
Kuba K; Yamaguchi T; Penninger JM
Front Immunol; 2021; 12():732690. PubMed ID: 35003058
[TBL] [Abstract][Full Text] [Related]
25. Polymorphisms of ACE (I/D) and ACE2 receptor gene (Rs2106809, Rs2285666) are not related to the clinical course of COVID-19: A case study.
Karakaş Çelik S; Çakmak Genç G; Pişkin N; Açikgöz B; Altinsoy B; Kurucu İşsiz B; Dursun A
J Med Virol; 2021 Oct; 93(10):5947-5952. PubMed ID: 34170561
[TBL] [Abstract][Full Text] [Related]
26. Receptor utilization of angiotensin-converting enzyme 2 (ACE2) indicates a narrower host range of SARS-CoV-2 than that of SARS-CoV.
Wang Q; Qiu Y; Li JY; Liao CH; Zhou ZJ; Ge XY
Transbound Emerg Dis; 2021 May; 68(3):1046-1053. PubMed ID: 32794346
[TBL] [Abstract][Full Text] [Related]
27. SARS-CoV-2/human interactome reveals ACE2 locus crosstalk with the immune regulatory network in the host.
Lite C; Ahmed SSSJ; Juliet M; Freddy AJ
Pathog Dis; 2021 Feb; 79(2):. PubMed ID: 33469663
[TBL] [Abstract][Full Text] [Related]
28. In silico studies on the comparative characterization of the interactions of SARS-CoV-2 spike glycoprotein with ACE-2 receptor homologs and human TLRs.
Choudhury A; Mukherjee S
J Med Virol; 2020 Oct; 92(10):2105-2113. PubMed ID: 32383269
[TBL] [Abstract][Full Text] [Related]
29. Discovery of human ACE2 variants with altered recognition by the SARS-CoV-2 spike protein.
Heinzelman P; Romero PA
PLoS One; 2021; 16(5):e0251585. PubMed ID: 33979391
[TBL] [Abstract][Full Text] [Related]
30. ACE2 models of frequently contacted animals provide clues of their SARS-CoV-2 S protein affinity and viral susceptibility.
Ma C; Gong C
J Med Virol; 2021 Jul; 93(7):4469-4479. PubMed ID: 33755203
[TBL] [Abstract][Full Text] [Related]
31. Mutants of human ACE2 differentially promote SARS-CoV and SARS-CoV-2 spike mediated infection.
Shukla N; Roelle SM; Suzart VG; Bruchez AM; Matreyek KA
PLoS Pathog; 2021 Jul; 17(7):e1009715. PubMed ID: 34270613
[TBL] [Abstract][Full Text] [Related]
32. Sex differences in COVID-19: candidate pathways, genetics of ACE2, and sex hormones.
Viveiros A; Rasmuson J; Vu J; Mulvagh SL; Yip CYY; Norris CM; Oudit GY
Am J Physiol Heart Circ Physiol; 2021 Jan; 320(1):H296-H304. PubMed ID: 33275517
[TBL] [Abstract][Full Text] [Related]
33. Classical and alternative receptors for SARS-CoV-2 therapeutic strategy.
Masre SF; Jufri NF; Ibrahim FW; Abdul Raub SH
Rev Med Virol; 2021 Sep; 31(5):1-9. PubMed ID: 33368788
[TBL] [Abstract][Full Text] [Related]
34. Increasing host cellular receptor-angiotensin-converting enzyme 2 expression by coronavirus may facilitate 2019-nCoV (or SARS-CoV-2) infection.
Zhuang MW; Cheng Y; Zhang J; Jiang XM; Wang L; Deng J; Wang PH
J Med Virol; 2020 Nov; 92(11):2693-2701. PubMed ID: 32497323
[TBL] [Abstract][Full Text] [Related]
35. Epigenetic alterations and genetic variations of angiotensin-converting enzyme 2 (ACE2) as a functional receptor for SARS-CoV-2: potential clinical implications.
Kianmehr A; Faraoni I; Kucuk O; Mahrooz A
Eur J Clin Microbiol Infect Dis; 2021 Aug; 40(8):1587-1598. PubMed ID: 33939044
[TBL] [Abstract][Full Text] [Related]
36. The role of microRNAs in modulating SARS-CoV-2 infection in human cells: a systematic review.
Marchi R; Sugita B; Centa A; Fonseca AS; Bortoletto S; Fiorentin K; Ferreira S; Cavalli LR
Infect Genet Evol; 2021 Jul; 91():104832. PubMed ID: 33812037
[TBL] [Abstract][Full Text] [Related]
37. Infectious Clones Produce SARS-CoV-2 That Causes Severe Pulmonary Disease in Infected K18-Human ACE2 Mice.
Liu X; Zaid A; Freitas JR; McMillan NA; Mahalingam S; Taylor A
mBio; 2021 Apr; 12(2):. PubMed ID: 33879586
[TBL] [Abstract][Full Text] [Related]
38. Differential expression in humans of the viral entry receptor ACE2 compared with the short deltaACE2 isoform lacking SARS-CoV-2 binding sites.
Williams TL; Strachan G; Macrae RGC; Kuc RE; Nyimanu D; Paterson AL; Sinha S; Maguire JJ; Davenport AP
Sci Rep; 2021 Dec; 11(1):24336. PubMed ID: 34934117
[TBL] [Abstract][Full Text] [Related]
39. SARS-CoV-2 Entry: At the Crossroads of CD147 and ACE2.
Fenizia C; Galbiati S; Vanetti C; Vago R; Clerici M; Tacchetti C; Daniele T
Cells; 2021 Jun; 10(6):. PubMed ID: 34201214
[TBL] [Abstract][Full Text] [Related]
40. Impact of Genetic Variability in ACE2 Expression on the Evolutionary Dynamics of SARS-CoV-2 Spike D614G Mutation.
Huang SW; Miller SO; Yen CH; Wang SF
Genes (Basel); 2020 Dec; 12(1):. PubMed ID: 33374416
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
